aTYR PHARMA (ATYR) Cash from Operations (2014 - 2026)

aTYR PHARMA (ATYR) has reported Cash from Operations for 13 consecutive years, with -$9.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 32.7% year-over-year to -$9.4 million; the trailing twelve-month figure through Jun 2026 stood at -$54.5 million (up 1.91% YoY), and the FY2025 full-year result was -$62.0 million, up 10.32% from the prior year.
• Cash from Operations climbed to -$9.4 million in Q2 2026 per ATYR's latest filing, from -$12.5 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$590000.0 in Q1 2023 and bottomed at -$22.4 million in Q1 2024.
• Historically, Cash from Operations has averaged -$12.7 million across 5 years, with a median of -$12.2 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations surged 94.17% in 2023, then slumped 3693.22% in 2024.
• Over 5 years, Cash from Operations stood at -$10.4 million in 2022, then retreated by 6.68% to -$11.1 million in 2023, then dropped by 18.71% to -$13.1 million in 2024, then rose by 7.13% to -$12.2 million in 2025, then gained by 23.33% to -$9.4 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$9.4 million, -$12.5 million, and -$12.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.